menorrhagia; this is a spontaneous report received from a contactable reporter (consumer or other non hcp) from the regulatory agency (ra). other case identifier(s): gb-mhra-adr 26595986 (ra), gb-mhra-vac-202202112213331190-uk7lc (ra). a 34 year-old female patient received bnt162b2 (bnt162b2), administration date 21jan2021 (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. relevant medical history included: "polycystic ovarian syndrome" (unspecified if ongoing). concomitant medication(s) included: levothyroxine. the following information was reported: heavy menstrual bleeding (medically significant) with onset 2021, outcome "not recovered", described as "menorrhagia". additional information: following vaccination, constant heavy vaginal bleeding has been experienced. this was still occurring 12 months after 1st vaccine dose. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected